Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]

View source ↗

Summary

Phase 3 trial update for atrasentan in IgA nephropathy is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy
• Immunoglobulin Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING